Antares Pharma — Shareholder Meeting (May 2006)
42 slides from Antares Pharma's shareholder meeting presentation, May 5, 2006
Slide 1: Antares Pharma Annual Meeting May 4, 2006
Strictly Confidential ANTARES PHARMA, INC. ANNUAL MEETING MAY 4, 2006 Amex: AIS www.antarespharma.com www.mediject.com Exhibit 99.1
Slide 2: Safe Harbor Statement
Antares Pharma, Inc. © 2006 Confidential This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that stateme
Slide 3: Agenda
Antares Pharma, Inc. © 2006 Confidential Overview Recent Accomplishments : Anturol™ Phase II results reported Estradiol Bio-E-Gel™ Other Financial Overview 2006 Value Drivers Agenda • • – – – • •
Slide 4: Overview
Strictly Confidential Overview
Slide 5: Overview
Antares Pharma, Inc. © 2006 Confidential Overview Organized by the Chairman, Jacques Gonella, Ph.D. (Jago Pharma) Three locations: Headquarters – Exton, PA Devices – Minneapolis, MN: Prototype modeling Pharma Development – Basel, Switzerland: GMP approved 27 employees 32 issued patents, 111 patents
Slide 6: Alliances and Partnerships
Alliances and Partnerships
Slide 7: Corporate Partners
Antares Pharma, Inc. © 2006 Confidential Corporate Partners
Slide 8: Business Model
Antares Pharma, Inc. © 2006 Confidential Business Model Validate technology with development partners Develop internal pipeline Out-license product rights in larger sectors Commercialize products in niche sectors of dermatology, pain, urology, CNS, and women’s health Acquire or license complimentary
Slide 9: Pharmaceutical Technology Platforms
Antares Pharma, Inc. © 2006 Confidential Pharmaceutical Technology Platforms EasyTec™ Orally Disintegrating Tablets Fast-Melt Tablet Technologies TecTix™ Transdermal/Topical Technology Eutectics Semisolid Technologies Topical Delivery Technology Local ATD ™ Combination Gels ATD ™ Single Gels Systemi
Slide 10: ATD Advanced Transdermal Delivery Technology
Antares Pharma, Inc. © 2006 Confidential ATD™ Advanced Transdermal Delivery Technology Antares Pharma Technologies: ATD™
Slide 11: Antares Pharma Technologies: ATD - What is it?
Antares Pharma, Inc. © 2006 Confidential Semi-solid formulations containing one or more drugs A hydro-alcoholic vehicle A combination of permeation enhancers Thickening agents A pH regulator Antares Pharma Technologies: ATD™ What is it? • • Increases drug partitioning into the skin Increases drug pa
Slide 12: Advantages of ATD Gels
Antares Pharma, Inc. © 2006 Confidential Antares Pharma Technologies: ATD™ Advantages of ATD™ Gels Reduces GI exposure Patented and able to deliver more than one drug • Avoids first - pass liver toxicity effects • • • Typically smaller doses • No irritation or occlusion • Leads to improved patient c
Slide 13: TecTix Transdermal/Topical Technology
Antares Pharma, Inc. © 2006 Confidential Antares Pharma Technologies: TecTix™ Eutectics Semisolid Technologies TecTix™ Transdermal/Topical Technology
Slide 14: Antares Pharma Technologies: TecTix - What is it?
Antares Pharma, Inc. © 2006 Confidential Melting point depression of API by Chemical Fragrance & Flavors Ingredients (CFFI) Versatile technology compatible with numerous API Alcohol-free liquid or semi-solid Patent-pending Technology (Priority date: August 23, 2005) What is it? Antares Pharma Techno
Slide 15: Advantages of TecTix
Antares Pharma, Inc. © 2006 Confidential CFFI with a long and safe history of use in toiletries, perfumes and cosmetics High thermodynamic activity Increase of lipophilic properties Higher dissolution rate faster onset-of-action Numerous API already successfully screened: NSAIDs Local anaesthetics N
Slide 16: EasyTec Oral Disintegrating Tablet Technology
Antares Pharma, Inc. © 2006 Confidential Fast Melt Tablet Technologies Antares Pharma Technologies: Easy Tec™ Easy Tec™ Oral Disintegrating Tablet Technology
Slide 17: Antares Pharma Technologies: EasyTec - What is it?
Antares Pharma, Inc. © 2006 Confidential - Hygroscopic disintegrant(s) - Water-soluble components - Large surface area (high porosity) Soft, friable, moisture-sensitive tablets The ideal ODT technology shall simultaneously achieve: 1) Rapid Oral Disintegration 2) Physical Stability AND EasyTec ODTs
Slide 18: EasyTec Main Advantages
Antares Pharma, Inc. © 2006 Confidential Simple and cost-effective Patented technology (US & EU) Superior palatability and mouth-feel Conventional packaging with low friability and moisture sensitivity Versatile for drug loadings Low cost of goods Antares Pharma Technologies: Easy Tec™ Main Advantag
Slide 19: Anturol ATD Gel
ANTUROL™ - ATD™ GEL
Slide 20: Anturol Market Positioning
Antares Pharma, Inc. © 2006 Confidential ATD ™ Oxybutynin Gel: Anturol ™ – Market Positioning Our innovative Overactive Bladder product will have… Fast onset of therapeutic activity Decreased incidence of systemic AE’s Lower incidence of local/on-site irritation Accurate, improved once-daily dosing
Slide 21: Anturol Phase II clinical study summary
Antares Pharma, Inc. © 2006 Confidential Anturol ATD™ Gel 48 subjects receiving three different treatments (low, intermediate, and high) over 20 consecutive days Anturol ATD™ Gel Phase II clinical study summary Dose proportionality and linear pharmacokinetics At intermediate dose, similar OXY averag
Slide 22: Indirect comparisons Cavg DEO/OXY levels
Antares Pharma, Inc. © 2006 Confidential Indirect comparisons Cavg DEO/OXY levels (Phase II) 3.0 4.3 5.4 3.0 4.0 7.0 4.2 10.1 4.5 60.4 12.7 5.8 0 10 20 30 40 50 60 70 80 OXY DEO Anturol™ Phase II Clinical Program DEO & OXY C avg (Surrogate for Efficacy) DITROPAN IR tablet 15mg/d DITROPAN XL tablet 1
Slide 23: Phase II adverse events: skin erythema
Antares Pharma, Inc. © 2006 Confidential Urology: Anturol™ ATD™ Gel Phase II adverse events: skin erythema Incidence of skin erythema: indirect comparison Anturol-Oxytrol 12 12 6 12 18 44 12 0 10 20 30 40 50 60 OXYTROL patch 36mg (delivers 3.9mg/d) ANTUROL gel low dose ANTUROL gel intermediate dose
Slide 24: Anturol ATD Gel Accomplishments
Antares Pharma, Inc. © 2006 Confidential Anturol ATD™ Gel Accomplishments Formulation development Completed First PK study in human Completed IND filing Completed Phase II study and report Completion in Jan 06 Tech-transfer Completion in Apr 06 End of Phase II meeting Completion in May 06 • • • • •
Slide 25: Anturol Phase III and Timelines
Antares Pharma, Inc. © 2006 Confidential Preliminary Phase III Currently under evaluation Urge and mixed urinary incontinence 12 week, Multi-center Two dose strengths, once daily, gel vs. placebo Scale-up to 500 kg batch size initiated with Patheon We have “freedom to operate” legal opinion Watson g
Slide 26: Other ATD Transdermal Gels
OTHER ATD™ TRANSDERMAL GELS
Slide 27: Bio-E-Gel
Antares Pharma, Inc. © 2006 Confidential Validated as first ATD™ product accepted by FDA Estrogen market $1.3 billion in U.S. and EU Market growing through 2010 Antares has milestones and royalties in U.S. Marketing rights in Europe and elsewhere Bio-E-Gel ™ NDA Accepted April 18, 2006 – – – – –
Slide 28: LibiGel Testosterone for FSD
Antares Pharma, Inc. © 2006 Confidential • ISSWSH Meeting in October 2005 reopened pathway • 240% increase in frequency of sexual activity. – No approved product in U.S. • 2006 Phase III Targeted by Partner – Phase II completed in 46 hysterectomized women, efficacious – Phase III clinical program de
Slide 29: Other Recent ATD Developments
Antares Pharma, Inc. © 2006 Confidential Development and license deals in CNS and Dermatology AP-1081 contraceptive ATD™gel: Ortho Evra® patch in preclinical AP-1022 Alprazolam ATD™gel: Xanax® for anti- anxiety disorders Other Recent ATD ™ Developments • • •
Slide 30: Antares Pharma
Me> antares pharma
Slide 31: AP-159 EasyTec ODT Tablet Accomplishments
Antares Pharma, Inc. © 2006 Confidential AP-159 Easy Tec™ Tablet Formulation development Completed 2005 In vitro dissolution test on final prototype Completed April 06 Manufacturing Tech-transfer Completed April 06 AP-159 Easy Tec™ ODT Tablet Accomplishments • • •
Slide 32: Antares Pharma
Me> antares pharma
Slide 33: Valeo/Vision Reusable Needle-Free Injectors
Antares Pharma, Inc. © 2006 Confidential • High-pressure for subcu delivery – Growing protein and macro - molecule markets (e.g. insulin, hGH, FSH, EPO, GCSF) • Insulin: Wal-Mart and Diabetic X • hGH field: Ferring and JCR • New Market in US • Insulin market: – Projected to grow from $7.7 billion in
Slide 34: Disposable Mini-Needle Injectors for Antidote Delivery
Antares Pharma, Inc. © 2006 Confidential Partner with government and private sector for bioterrorism Patented, pre-packed, portable, low cost, durable in adverse conditions BioShield: $5.6 billion for government procurement Does not require FDA approval Disposable Mini-Needle Injectors For Antidote
Slide 35: TEVA Injector Deal
Antares Pharma, Inc. © 2006 Confidential First commercial deal in device category Exclusive supplier Ramping up of product line currently Transfer price, royalties and milestones also TEVA Injector Deal November 28, 2005 • • • •
Slide 36: Financial Overview
Financial Overview
Slide 37: Financial Overview
Antares Pharma, Inc. © 2006 Confidential Financial Overview Market Cap $90 mm Shares Outstanding 53 mm Fully Diluted Shares 80 mm Diluted Shares in Money 73 mm Cash + Cash Equivalents $2.7 mm As of 12/31/05 Debt / Pfd Stock NONE As of 3/28/06 * * In the 1 st Qtr of 2006 AIS raised $10 mm Amex: AIS A
Slide 38: Recent Accomplishments
RECENT ACCOMPLISHMENTS
Slide 39: Summary of Recent Accomplishments
Antares Pharma, Inc. © 2006 Confidential Summary of Recent Accomplishments Positive Phase II results, Anturol™ NDA for Bio-E-Gel ™, estradiol ATD™ gel accepted by FDA First commercial injector deal with TEVA Added new CFO, Robert F. Apple Raised $11 million Announced TecTix™ DD system • • • • • •
Slide 40: Antares Pharma
Me> antares pharma
Slide 41: 2006 Key Value Drivers
Antares Pharma, Inc. © 2006 Confidential 2006 Key Value Drivers Initiate Phase III Clinicals for Anturol™ Next mini-needle (Vibex™) disposable injector deal Expand market for hGH opportunity First formulation of first TecTix™ product • • • •
Slide 42: Strictly
Strictly Confidential